(Q36206605)

12 August 2017

1 reference

title

Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia (English)

1 reference

12 August 2017

Ajay Nehra

1

1 reference

12 August 2017

1 August 2005

1 reference

12 August 2017

1 reference

12 August 2017

96

1 reference

12 August 2017

3

1 reference

12 August 2017

237-243

1 reference

Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Prostate and sexuality: An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Global perspectives and controversies in the epidemiology of male erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: the Krimpen study of male urogenital tract problems and general health status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Sexual dysfunction in men with lower urinary tract symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Sexual function in 131 patients with benign prostatic hyperplasia before prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05610.X

10.1111/J.1464-410X.2005.05610.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16042709